# Opportunity page new layout

We're excited to announce a redesign of the opportunity page! This update will help you stay more productive and focused, ensuring that important details are always up-to-date and readily accessible.

Key improvements include:

- **Reduced number of tabs:** We've reorganized tabs so that all available information is always visible, in panel view or full page view, without having to scroll.
- **Improved information grouping:** Information is now more logically grouped, making it easier to find and update key details without navigating multiple tabs.
- **Task and evaluation panel:** To ensure tasks can be created anytime while working on your opportunities, they can now be opened as a panel from the top menu.
- Action cards: Four action cards have been added to the *Overview* tab to give you the latest updates on your meetings, comments, tasks and evaluations.



#### Larger Workspace

The static elements on the right-side of the page have been moved to free space for more actionable information.

1 The CDAs, the Connect Campaign and the Due Diligence Module integrations have been moved to the *Overview* tab.

Tags have been moved to the *Details* tab.

AFTER

BEFORE

e Back	MS 🗃 😹 View access :
Company     Active      Active	CDA Active View A Effective date Sat Sep 29, 2029 Due Diligence A
Overview Asset Details Summary Attachments 0 Tasks 2 Meetings 0 Contacts 0 Agreements 0 Status update	@Send to Due Diligence  fs Inpart Connect Connection request Connection status
Opportunity overview	Not requested Request connection Submission type spinout
Related companies	Tags Tags IB/02022 © 1 Research Proj © 1 Technology © Bearch for ~

ABC-26723										
O Active V	MS Melissa Scott	ABC Pharma CDA +1								
		•		· · ·	· · ·					
Identification Jan 2, 2024	Screening Jan 3, 2024	Confidential Evaluation Jul 19, 2024 View Instructions	Due Diligence	Negotiation	Contracti	ng Sig	ned			
Overview Details Me	etings 0 Contacts 3 Att	achments 3 Related information								
📋 0 meetings in last 30	days	3 comments in last 30 days		1 ongoing evaluation		☑ 3 open tasks				
Status update Last updated on Jul 19,	2024 by MS Melissa Scott		+ Add new i	CDA O Active			View ^			
Updates				Effective date Wed, Sep 25, 2024		Expiration date Mon, Sep 24, 2029				
Cross-functional	meeting with company to be sch	reduled if feedback is positive.		Due Diligence			1			
Next steps				Send to Due Diligenc	8					
Check on data ava	allability to pursue further.			tu Inpart Connect Connection re	equest		^			
Notes Last updated 2 weeks	Overview Details Meeti	ngs 0 Contacts 3 Attachm	nents 3 Related	information						
	Orphan Drug ) Out-lice	ensing 🗿 Search for tags						2		~
	Pharma asset			🖉 Edit 🗸 🗸	Opportunity mar	nagement		/	Edit	~
	Scientific classif	ication		🖉 Edit 🗸 🗸	Financial informa	ation		/	Edit	~

## One single Information Tab

## All information fields have been grouped under the *Details* tab to ease the navigation

- The Opportunity overview section has been moved to the Details tab and renamed General information.
- All fields in the *Asset* tab have been moved the *Details* tab.
- Tags can now be found at the top of the *Details* tab.

AFTER

é Back			e Back						왕 View access : : 문
a DAE-123			ABC-26723						
Status Devest by Company Agreements O Active V III Melissa Scott Dejeon Biometrics None			Active      Melitss	a Scott 🔲 ABC Pharma	CDA Licensing				
Identification Screening To be defined			Identification Jan 2, 2024	Screening Jan 8, 2024	Confidential Evaluation Jul 19, 2024 View Instructions	Due Dillgence	Negotiation	Contracting	Signed
			Overview Details Attachments 3	Meetings 2 Contacts 3 Related info	rmation				
Overview Asset Details Summary Attachments 0 Tasks 2 Meetings 0 Contacts 0 Agreements 0			Search for tags						
Status update			Pharma asset			🖉 Edit 🗸 🗸	Opportunity management		
Add updates and next steps			Scientific classification		2	🖉 Edit	Financials		
Opportunity overview v			Pharma assessment			🖉 Edit	Intellectual Property		
Related companies • + Add · ·			Territories			🖉 Edit	General information		
Related opportunities 0 Overview Asset Details Summary Attachments 11	Tasks 0 Meetings 0 Contacts 0 Agreements 1						General	Asset t	ype -
							Opportunity type	👗 Pha	ma asset
Pharma asset	2 Edit V						Discovery		
Scientific classification	Edit V						Discovered on Jan 2, 2024	Discov PS Pr	ered by syash Shah
							Source Conference	Source BIO As:	conference a
Pharma assessment	🖉 Edit						Source details		
	Back DAE-123      Orected     Content by     In Medicas Scott     Orecyce     Asset     Content by     In Medicas Scott     Orecyce     Aug 20, 2023     Soreening     Contents     Contents     Soreening     Contents     Contents     Soreening     Contents     Soreening     Contents     Contents     Soreening     Contents     Contents     Soreening     Contents     Contents     Soreening     Contents     Contents     Contents     Soreening     Contents     Contents     Soreening     Contents     Content     Content     Content     Contents     Cont	Bach DAE-123      More we	Image: Summary Attachments I Task I Meeting I Contacts I Agreements I	Set   DATE   DATE   DATE   Defende form   De	<pre>***</pre>	<pre>****</pre>	Interview   Interview Interview   Interview Interview		

**BEFORE** 

### Practical **Overview**

## The *Overview* tab now groups the most frequently used features and gives a quick outlook of the opportunity state

The *Status update* and the *Notes* (previously in the *Summary* tab) are now easily accessible in the *Overview* tab.

2) The CDA information, and the Due Diligence and Connect integrations are now quickly visible in the Overview tab.

Action cards tell at a glance if meetings recently happened, if comments were recently adedd, and if any evaluations or tasks are currently open.

		ABC-26723           Active ~           Melissa Scott           ABC Pharma           CDA +1
ABC-55		
Status         Owned by         Company         Agreements           O Active         Ms         Mellissa Scott         III APIC/PRU         CDA	CDA ( Active View A	Identification Screening Confidential Evaluati Due Diligence Negotiation Contracting Signed Jan 2, 2024 Jan 3, 2024 Jul 19, 2024 View instructions
Identification Confidential Evol Duo Dillocence Manetistice Controllice Classed	Effective date Expiration date Wed, Oct 9, 2024 Mon, Oct 8, 2029	
Mar 21, 2024 Mar 21, 2024 Mar 21, 2024		Overview Details Meetings (2) Contacts (3) Attachments (3) Related information
Overview Asset Details Summary ttachments 0 Tasks 8 Meetings 0 Contacts 0 Agreements 1	@Send to Due Diligence	🗁 2 meetings in last 30 days 💭 3 comments in last 30 days 👘 1 ongoing evaluation 🗸 3 open tasks
Status update Add updates and next steps + Add	*s Inpart Connect Connection request	Status update     + Add new       Last updated on Jul 19, 2024 by MS     Mellssa Scott
Opportunity overview $\checkmark$	Connection status Pending Cancel connection Submission type Blopharma Asset	Updates Effective date Expiration date Wed, Sep 25, 2024 Mon, Sep 24, 2029
Related companies • + Add •		Cross-functional meeting with company to be scheduled if feedback is     positive.     Due Diligence     2
		Next steps
Related opportunities 0 + Add V		Check on data availability to pursue further.
		Connection request
		Notes     Submission type       Last updated 2 weeks ago by Vis Mellissa Scott     Biopharma Asset

**BEFORE** 

#### Accessible **Tasks**

## Create and manage your tasks and evaluations at anytime from the header

A task button has been added to the header to open the new Tasks and Evaluations panel.

The avatars of the users with access to the opportunity have been removed to save space and gain clarity. The full list of users is still available from the *View access* button.

RE		AFTER
(+ Back	MS & & View access 1 8 4% 00	E Back
Constitute     Constitute	Due Diligence	DAE-123       Active       Echo Zhang       Mitsubishin       Stew access       Image: Constraint of the state
Overview Asset Details Summary Attachments (0) Tasks (2) Meetings (0) Contacts (0) Agreements (0)	@Send to Due Diligence 1. Inpert Connect Connection request	Overview Details Attachments 11 Meetings 0 Contacts 0 Related information
Status update       Add updates and next steps       Opportunity overview	Connection status Not requested Submission type spinout	
Related companies  + Add	Tags	
Related opportunities • + Add •	BIO2022 © TResearch Proj. © Technology © Search for V	

BEFC

#### Visible **Tabs**

**BEFORE** 

## The number of tabs have been ensure to ensure they were all visible at all times

The Related companies and Related opportunities sections have been moved to the new Related information tab.

The Agreements tab has also been merged into the Related information tab.

← Back			
6 DAE-123			
O Active V	Owned by MB Melisse Scott	Comoleny	Apparents None
	0		
Identification Aug 2, 2024	Screening Aug 29, 2024	To be defined	DAE-123
			Status         Owned by         Company         Agreements           Q Active ~         IZ Echo Zhang         Mitsubishi Tanabe         CDA
Overview Asset De	tails Summary Attachmen	ts O Tasks 2 Meetings	•
Status update Add updates and ne	xt steps		Identification Screening Confidential Eval Due Diligence Negotiation Contracting Signed Mar 7, 2023 Mar 13, 2023 Mar 13, 2023 Apr 5, 2023 Feb 16, 2024
Opportunity o	overview		Overview Asset Details Summary Attachments 11 Tasks 2 Meetings 2 Contacts 2 Agreements 3
Related comp	anies 0	1	Agreements 3 + Add
Related oppo	rtunities 0	U	Search Type Status
			Title Type Status $\uparrow$ Effective date Expiration date
			CDA with Mitsubishi Tanabe Pharma Corporati CDA O Active V Sep 30, 2024 Sep 29, 2029
			CDA with Mitsubishi Tanabe Pharma Corporati CDA O Active V Sep 30, 2024 Sep 29, 2029
			CDA with Mitsubishi Tanabe Pharma Corporati CDA O Active V Sep 30, 2024 Sep 29, 2029

#### AFTER ← Back & View access ABC-26723 Active Identification Confidential Evaluation Due Diligence Contracting Screening Negotiation Signed Overview Details Attachments 3 Meetings 2 Contacts 3 Related informatio Agreements 2 + Add 🗸 🗸 **Opportunities** + Add Companies + Add 🗸 🗸

## Simpler **Header**

## Subtitles have been removed from the headline's details to gain space and clarity

The information remains the same, but the field titles are now displayed within tooltips when hovering over the information. As a reminder, the fields available are the opportunity status, the opportunity owner, the company evaluated in the opportunity, and the types of the agreements attached to the opportunity.

**AFTER** 

← Back			a View acc	955 : BØ 4 G
DAE-123				
Status Owned by O Active V IZ Echo Zhar	rg Dompany Agreements CDA		CDA O Active	View
	•		Effective date Mon. Sep 30, 2024	Expiration date Sat Sep 20, 2020
Status	Owned by	Company		Agreements
O Active 🗸	EZ Echo Zhang	📱 Mitsubish	i Tanabe	CDA
Status update		Add new 1	Expired Submission type	
Added on Sep 30, 2024 MS Melissa Scott			Research Project	
Updates			Tags	

DAE-123			
O Active	ho Zhang 🔲 Mitsubishi Tanabe CDA		
O Active V	MS Melissa Scott	🖫 ABC Pharma	CDA + 1
		0	Agreement type: Confidential Disclosure Agreement, Licensing
🛱 2 meetings in last 30 days	C 0 comments in last 30 days	ជឿ longoing evaluation	0 open tasks